|Mr. Michael L. Favet||Pres, CEO & Director||835.42k||N/A||1970|
|Ms. Irina Ridley||Gen. Counsel & Corp. Sec.||462.11k||N/A||1986|
|Dr. Martha J. Morrell||Chief Medical Officer||583.5k||N/A||1957|
|Ms. Rebecca L. Kuhn||CFO, VP of Fin. & Admin. and Assistant Sec.||N/A||N/A||1961|
|Ms. Chi Nguyen||VP of Marketing||N/A||N/A||1977|
|Mr. Mark S. Saxton||VP of Sales||N/A||N/A||1965|
|Ms. Irene Thomas||VP of HR||N/A||N/A||1969|
|Mr. Andre G. Marquette||Chief Commercial Officer||N/A||N/A||N/A|
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
NeuroPace, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.